Analyse Imunon, Inc. (IMNN) — Kairos Score 43/100

À propos de Imunon, Inc.

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Informations clés

🕴️ Activité des initiés (90 jours)

16 transactions — 0 achats et 2 ventes déclarés par les dirigeants de Imunon, Inc..

🏦 Hedge Funds

2 fonds institutionnels déclarent une position sur IMNN dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur IMNN.

• IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer
• IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.